Pharmaceutical Chemistry Department, Faculty of Pharmacy, Misr International University, Cairo 11431, Egypt.
Pharmaceutical Chemistry Department, Faculty of Pharmacy, Damanhur University, Damanhur, Egypt.
Bioorg Chem. 2014 Dec;57:65-82. doi: 10.1016/j.bioorg.2014.08.006. Epub 2014 Sep 3.
In this study, five series of (E)-6-(4-substituted phenyl)-4-oxohex-5-enoic acids IIb-f (E), (E)-3-(4-(substituted)-phenyl)acrylic acids IIIa-g (E), 4-(4-(substituted)phenylamino)-4-oxobutanoic acids VIa,b,e, 5-(4-(substituted)phenylamino)-5-oxopentanoic acids VIIa,f and 2-[(4-(substituted)phenyl) carbamoyl]benzoic acids VIIIa,e were designed and synthesized. Selected compounds were screened in vitro for their cytotoxic effect on 60 human NCI tumor cell lines. Compound IIf (E) displayed significant inhibitory activity against NCI Non-Small Cell Lung A549/ATCC Cancer cell line (68% inhibition) and NCI-H460 Cancer cell line (66% inhibition). Moreover, the final compounds were evaluated in vitro for their cytotoxic activity on HepG2 Cancer cell line in which histone deacetylase (HDAC) is overexpressed. Compounds IIc (E), IIf (E), IIIb (E), and IIIg (E) exhibited the highest cytotoxic activity against HepG2 human cancer cell lines with IC50 ranging from 2.27 to 10.71μM. In addition, selected compounds were tested on histone deacetylase isoforms (HDAC1-11). Molecular docking simulation was also carried out for HDLP enzyme to investigate their HDAC binding affinity. In addition, generation of 3D-pharmacophore model and quantitative structure activity relationship (QSAR) models were combined to explore the structural requirements controlling the observed cytotoxic properties.
在这项研究中,设计并合成了五组(E)-6-(4-取代苯基)-4-氧代己-5-烯酸 IIb-f(E)、(E)-3-(4-(取代)-苯基)丙烯酸 IIIa-g(E)、4-(4-(取代)苯基氨基)-4-氧代丁酸 VIa,b,e、5-(4-(取代)苯基氨基)-5-氧戊酸 VIIa,f 和 2-[(4-(取代)苯基)氨甲酰基]苯甲酸 VIIIa,e。选择的化合物在体外对 60 个人类 NCI 肿瘤细胞系进行了细胞毒性筛选。化合物 IIf(E)对 NCI 非小细胞肺癌 A549/ATCC 癌细胞系(68%抑制)和 NCI-H460 癌细胞系(66%抑制)显示出显著的抑制活性。此外,还评估了最终化合物对人肝癌 HepG2 细胞系的体外细胞毒性,该细胞系中组蛋白去乙酰化酶(HDAC)过表达。化合物 IIc(E)、IIf(E)、IIIb(E)和 IIIg(E)对 HepG2 人癌细胞系表现出最高的细胞毒性活性,IC50 范围为 2.27 至 10.71μM。此外,还对组蛋白去乙酰化酶同工酶(HDAC1-11)进行了测试。还进行了分子对接模拟,以研究它们与 HDLP 酶的 HDAC 结合亲和力。此外,还结合生成了 3D 药效团模型和定量构效关系(QSAR)模型,以探讨控制观察到的细胞毒性特性的结构要求。